- Home
- ENLT vs PODD Comparison
ENLT vs PODD Comparison
Compare ENLT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLT | PODD |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | Israel | United States |
| Employees | 406 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.2B |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ENLT | PODD |
|---|---|---|
| Price | $68.77 | $133.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 21 |
| Target Price | $48.83 | ★ $341.48 |
| AVG Volume (30 Days) | 142.8K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.67 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $403.69 | $24.55 |
| Revenue Next Year | N/A | $19.18 |
| P/E Ratio | $76.10 | ★ $51.01 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $29.65 | $126.40 |
| 52 Week High | $108.65 | $354.88 |
Technical Indicators
Market Signals| Indicator | ENLT | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 35.48 | 34.88 |
| Support Level | $65.61 | $131.24 |
| Resistance Level | $78.17 | $153.33 |
| Average True Range (ATR) | 1.72 | 4.39 |
| MACD | -0.25 | -0.25 |
| Stochastic Oscillator | 7.16 | 14.58 |
Price Performance
Historical ComparisonAbout ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, producing its revenue from the sale of the electricity which is produced through wind energy and solar energy in Europe.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.